Stockscreener 앱 받기
0.08%
시장 영업 전:
전일 마감가:
$25.06
열려 있는:
$25.11
하루 거래량:
86.26M
Relative Volume:
1.35
시가총액:
$220.29B
수익:
$62.79B
순이익/손실:
$9.84B
주가수익비율:
14.62
EPS:
1.7156
순현금흐름:
$10.38B
1주 성능:
+2.83%
1개월 성능:
+2.33%
6개월 성능:
+9.86%
1년 성능:
+1.13%
1일 변동 폭
$24.95
$25.57
1주일 범위
$24.44
$26.48
52주 변동 폭
$20.91
$27.69
화이자 Stock (PFE) Company Profile
명칭
Pfizer Inc
전화
(212) 733-2323
주소
66 HUDSON BOULEVARD EAST, NEW YORK, NY
PFE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.08 | 142.48B | 62.79B | 9.84B | 10.38B | 1.7156 |
|
LLY
Lilly Eli Co
|
1,021.70 | 917.64B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
199.58 | 472.05B | 92.15B | 25.12B | 20.46B | 10.36 |
|
AMGN
Amgen Inc
|
341.71 | 181.33B | 35.89B | 7.01B | 11.54B | 12.94 |
|
ABBV
Abbvie Inc
|
234.00 | 410.67B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
MRK
Merck Co Inc
|
92.86 | 230.63B | 63.90B | 19.05B | 13.05B | 7.5596 |
화이자 Stock (PFE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-25 | 재개 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | 다운그레이드 | Argus | Buy → Hold |
| 2024-02-23 | 개시 | Guggenheim | Buy |
| 2024-01-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-10-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-17 | 재확인 | JP Morgan | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-06-29 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-01-17 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-20 | 재확인 | Cowen | Outperform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-13 | 업그레이드 | UBS | Neutral → Buy |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-12-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 재개 | Goldman | Neutral |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-10-12 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-16 | 개시 | SVB Leerink | Mkt Perform |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-27 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-07-30 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 재개 | Morgan Stanley | Overweight |
| 2019-02-20 | 재개 | Citigroup | Neutral |
| 2019-01-31 | 업그레이드 | Argus | Hold → Buy |
| 2019-01-31 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2018-12-11 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-01 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
모두보기
화이자 주식(PFE)의 최신 뉴스
Novo Nordisk's New Chair Aims To Reinforce Board As Foundation Tightens Control - Benzinga
Daiwa Securities Adjusts Price Target on Pfizer to $27 From $29, Maintains Outperform Rating - MarketScreener
Pfizer launches new medication for migraine treatment - BusinessLine
Down 55%, Should You Buy the Dip on Pfizer? - Yahoo Finance
Pfizer completes acquisition of Metsera - Medical Dialogues
Novo Chairman Blames Board Dropout on Former Employer Pfizer - livemint.com
Values that Pfizer and Delta CEOs draw on for great leadership - Yahoo Finance
Analysts’ Top Healthcare Picks: Candel Therapeutics (CADL), Pfizer (PFE) - The Globe and Mail
Pfizer's Rich Dividend Story Meets Overpriced Metsera Acquisition/Patent Cliff Risks - Seeking Alpha
Is Pfizer Stock a Buy After This $10 Billion Acquisition? - MSN
A Look at BioNTech (NasdaqGS:BNTX) Valuation Following Pfizer’s Share Sale Announcement - Yahoo Finance
Starboard Value Calls It Quits On Its Pfizer Investment - Finimize
Activist Starboard sells Pfizer stake after pushing for changes - Reuters
Starboard Value Takes Significant Stake in BILL, Exits Pfizer - GuruFocus
Starboard's Q3 moves show previously disclosed new stake in BILL, Pfizer exit (BILL:NYSE) - Seeking Alpha
Law360 Pulse Spotlight On Mid-Law Work - Law360
Starboard Value LP dissolves share stake in Pfizer & Fortrea - MarketScreener
Taxation With Representation: Wachtell, Paul Hastings, Sidley - Law360
Metsera acquisition 'could be a key tailwind' for Pfizer - The Business Journals
Why Pfizer (PFE) Shares Are Sliding Today - Finviz
Pfizer 3Q Results - Contract Pharma
Novo’s new chairman urged to curb risk after Metsera drama - The Detroit News
Pfizer Reportedly Planning To Divest BioNTech Stake - BioSpace
New GIPR antagonists disclosed in Pfizer patent - BioWorld MedTech
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Rothschild & Co Redburn Adjusts Price Target on Pfizer to $24 From $25, Maintains Neutral Rating - MarketScreener
Pfizer Cuts BioNTech Stake by More Than Half - TradingView
Why analysts remain bullish on Pfizer Inc. stockTrade Analysis Report & Weekly Stock Performance Updates - Fundação Cultural do Pará
Will Pfizer Inc. stock test record highs in 2025July 2025 Pullbacks & Low Risk Entry Point Guides - Fundação Cultural do Pará
Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal - Yahoo Finance
Pfizer Stock Slips Premarket Despite Completing Metsera Deal; Investors React To BioNTech Stake Cut - Stocktwits
Pfizer Strengthens Pipeline With $10B Metsera Deal Amid Solid Q3 Results - Seeking Alpha
Pfizer completes Metsera acquisition in deal worth up to $10 bn - El Paso Inc.
Pfizer’s former R&D chief Dolsten pulls out of Novo Nordisk board race - 104.1 WIKY
Pfizer And Novo Nordisk Make Major Moves In Health Care - Finimize
Pfizer Buys Metsera To Jumpstart Its Obesity Drug Ambitions - Finimize
Pfizer's $10 Billion Obesity Drug Deal Could Reshape Treatment for 137 Million Americans - Stansberry Research
Pfizer slashes stake in COVID vaccine partner BioNTech - 104.1 WIKY
AK Health Dept. mails Pfizer-funded flyers telling Alaskans to vax to avoid illness, death - Alaska Watchman
Pfizer's former R&D chief Dolsten pulls out of Novo Nordisk board race - MarketScreener
Pfizer's ex-R&D chief Dolsten withdraws from Novo Nordisk board race - Yahoo Finance
Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up By Reuters - Investing.com
Pfizer Slashes Stake in COVID Vaccine Partner BioNTech - US News Money
Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up - MarketScreener
Wachtell-Led Pfizer Closes Metsera Deal Worth Up To $10B - Law360
Pfizer Completes Acquisition of Metsera for $7 Billion - TipRanks
Pfizer completes $7 billion acquisition of Metsera with milestone payments - Investing.com
Pfizer completes $7 billion acquisition of Metsera with milestone payments By Investing.com - Investing.com South Africa
Pfizer CEO says RFK Jr. wasn't his 'first choice' for HHS Secretary - Yahoo Finance
Pfizer CEO vows company will be a ‘formidable competitor’ in booming weight-loss market after $10B buy - MSN
Metsera holders vote to approve $10B sale to Pfizer, deal closes (update) (MTSR:NASDAQ) - Seeking Alpha
화이자 (PFE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.06%
0.34%
자본화:
|
볼륨(24시간):